MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
An Update on Peripheral Brachytherapy
Vascular brachytherapy still plays a role in the current treatment of restenosis.
By Ron Waksman, MD, FACC
Biotronik’s Passeo-18 Lux DCB Evaluated in 5-Year Patient-Level Safety Data
April 28, 2022—Biotronik announced that new long-term data demonstrated the safety of the company’s Passeo-18 Lux paclitaxel drug-coated balloon (DCB) for the treatment of peripheral artery disease (PAD) in infrainguinal arteries.
An Interview with Stephen R. Ramee, MD
A premier interventional cardiologist discusses the success of All That Jazz 2006 after Katrina and collaboration to treat stroke.
By Stephen R. Ramee, MD
ISET Panel Considers Future of Renal Denervation to Treat Hypertension
February 2, 2015—A panel at ISET 2015: the International Symposium on Endovascular Therapy in Hollywood, Florida, discussed the past and future investigations of renal denervation (RDN) as therapy for treatment-resistant hypertension (HTN).
Restenosis Management
By John R. Laird, Jr, MD Chief Medical Editor
Biotronik’s Passeo-18 Lux DCB Evaluated in Two Studies of Challenging Femoropopliteal Lesions
July 6, 2022—Biotronik announced the presentation of two studies on the performance of its Passeo-18 Lux drug-coated balloon (DCB) catheter at LINC 2022, the Leipzig Interventional Course held June 6-9 in Leipzig, Germany.
Overview of Restenosis in Peripheral Arterial Interventions
Restenosis continues to complicate percutaneous procedures, but new treatments hold promise.
By Robert S. Dieter, MD, RVT, and John R. Laird, Jr, MD
